These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26820375)

  • 1. Dopamine improves exploration after expectancy violations and induces psychotic-like experiences in patients with Parkinson's disease.
    Polner B; Moustafa AA; Nagy H; Takáts A; Győrfi O; Kéri S
    Neurosci Lett; 2016 Mar; 616():132-7. PubMed ID: 26820375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
    Mongeon D; Blanchet P; Messier J
    Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
    Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
    Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
    Righi S; Viggiano MP; Paganini M; Ramat S; Marini P
    Neuropsychologia; 2007 Oct; 45(13):2931-41. PubMed ID: 17662314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.
    Geiser E; Kaelin-Lang A
    Behav Brain Res; 2011 Nov; 225(1):270-5. PubMed ID: 21787806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease.
    Hälbig TD; Assuras S; Creighton J; Borod JC; Tse W; Frisina PG; Voustianiouk A; Gracies JM; Olanow CW
    Mov Disord; 2011 Aug; 26(9):1677-83. PubMed ID: 21638322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
    Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
    Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopaminergic medication counteracts conflict adaptation in patients with Parkinson's disease.
    Duthoo W; Braem S; Houtman F; Schouppe N; Santens P; Notebaert W
    Neuropsychology; 2013 Sep; 27(5):556-61. PubMed ID: 23815093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the acute contributions of dopaminergic replacement to gait with obstacles in Parkinson's disease.
    Pieruccini-Faria F; Vitório R; Almeida QJ; Silveira CR; Caetano MJ; Stella F; Gobbi S; Gobbi LT
    J Mot Behav; 2013; 45(5):369-80. PubMed ID: 23834709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verbal fluency in Parkinson's disease patients on/off dopamine medication.
    Herrera E; Cuetos F; Ribacoba R
    Neuropsychologia; 2012 Dec; 50(14):3636-40. PubMed ID: 22995942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oscillatory subthalamic nucleus activity is modulated by dopamine during emotional processing in Parkinson's disease.
    Huebl J; Spitzer B; Brücke C; Schönecker T; Kupsch A; Alesch F; Schneider GH; Kühn AA
    Cortex; 2014 Nov; 60():69-81. PubMed ID: 24713195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical practice. Diagnosis and initial management of Parkinson's disease.
    Nutt JG; Wooten GF
    N Engl J Med; 2005 Sep; 353(10):1021-7. PubMed ID: 16148287
    [No Abstract]   [Full Text] [Related]  

  • 18. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment.
    Blandini F; Cosentino M; Mangiagalli A; Marino F; Samuele A; Rasini E; Fancellu R; Tassorelli C; Pacchetti C; Martignoni E; Riboldazzi G; Calandrella D; Lecchini S; Frigo G; Nappi G
    J Neural Transm (Vienna); 2004 Aug; 111(8):1017-30. PubMed ID: 15254790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW; Kang SY; Sohn YH
    Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosis in Parkinson's disease.
    Poewe W
    Mov Disord; 2003 Sep; 18 Suppl 6():S80-7. PubMed ID: 14502660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.